Correlation between Vitamin D Receptor SNP ApaI and liver fibrosis in HCV patients from Thrace

Size: px
Start display at page:

Download "Correlation between Vitamin D Receptor SNP ApaI and liver fibrosis in HCV patients from Thrace"

Transcription

1 Correlation between Vitamin D Receptor SNP ApaI and liver fibrosis in HCV patients from Thrace A. Beka 1, T. Mylopoulou 2, V. Papadopoulos 2, I. Karakasiliotis 2, P. Mavromara 1, K. Mimidis 2, S. Veletza 2 1 DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS, DEMOCRITUS UNIVERSITY OF THRACE, ALEXANDROUPOLIS, GREECE 2 DEPARTMENT OF MEDICINE, DEMOCRITUS UNIVERSITY OF THRACE, ALEXANDROUPOLIS, GREECE

2 HCV infection is a major public health problem 71 million with chronic HCV infection worldwide (1% of the population.) 1.75 million new infections in 2015 ~ deceased yearly 15-45% spontaneous clearance There is no vaccine available Global Hepatitis Report Geneva: World Health Organization; Licence: CC BY- NC-SA 3.0 IGO

3 Pathogenesis of HCV infection Normal Chronic Liver Liver Hepatocellular Liver Infection Steatosis Cirrhosis Carcinoma Ke and Chen (2012) Hepatitis C Virus and Cellular Stress Response: Implications to Molecular Pathogenesis of Liver Diseases. Viruses (doi: /v ), edited

4 Hepatitis C virus Member of the Flaviviridae family - Hepacivirus genus Positive-sense single stranded RNA Blausen Medical Communications Abdel-Hakeem MS and Shoukry NH (2014) Protective immunity against hepatitis C: many shades of gray. Front. Immunol. 5:274. doi: /fimmu

5 HCV has an increased genetic heterogeneity HCV genotype influences the outcome of PEG- IFN/RBV therapy and viral pathogenicity Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T. and Simmonds, P. (2014), Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 59: doi: /hep.26744

6 The role of host genetic heterogeneity in HCV infection IFNL3 C/C IFNL4 T/T HCV-1,2,3 and 4Higher RVR rates MTTP TT or TG HCV-3 Higher levels of liver steatosis VDR bat haplotype CCA and ApaI CC HCV-1/2/3 Swiss patients Rapid fibrosis Riva et al, review, Clinical Microbiology and Infection, 2014, Zampino et al, Journal of Viral Hepatitis, 2008, Baur et al, Liver International, 2012

7 Why VDR? Low 25(OH) D levels are correlated to advanced fibrosis. VDR polymorphisms have been associated with rapid fibrosis progression in HCV patients from Switzerland and Brazil Petta et al, 2010, Baur et al, 2012, Paula Scalioni et al 2018, Gascon-Barre et al, 2003

8 Aim To investigate the possible association of VDR ApaI (rs ) genotype of HCV monoinfected patients from Thrace-Greece with the stage of liver fibrosis.

9 Experimental design HCV RNA positive FibroScan Collecting blood samples DNA isolation PCR ApaI Digestion Gel Electrophoresis Patient characteristics n = 67 Gender (Male/Female) 46/21 Age Average 52 (22-78) Ethnicity Caucasian (100%) HCV genotype 1 36 HCV genotype 3 22 HCV non1-non3-genotype 9 FibroScan FibroScan 2 10 FibroScan 3 8 FibroScan 4 / Cirrhotic 24 FibroScan Interpretation F kpa F2 7-9 kpa F kpa F kpa

10 Experimental design HCV RNA positive FibroScan Collecting blood samples DNA isolation PCR ApaI Digestion Gel Electrophoresis Credit: Genome Decoration Page /NCBI CAGAGCATGGACAGGGAGCAAGGCCAGGCAGGGACAGGGCCAGGTGCGCCCATGGAAGGACCTAGGTC TGGATCCTAAATGCACGGAGAAGTCACTGGAGGGCTTTGGGGCCAGGCAGTGGTATCACCGGTCAGCAGTCATAGA GGGGTGGCCTAGGGGGTGCTGCCGTTGAGTGTCTGTGTGGGTGGGGGGTGGTGGGATTGAGCAGTGAGGGGC CCAGCTGAGAGCTCCTGTGCCTTCTTCTCTATCCCCGTGCCCACAGATCGTCCTGGGGTGCAGGACGCCGCGCTGAT CGAGGCCATCCAGGACCGCCTGTCCAACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCAC CTGCTCTATGCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAGTACCGCTG CCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAAGTGTTTGGCAATGAGATCTCCTGACT AGGACAGCCTGTGGCGGTGCCTGGGTGGGGCTGCTCCTCCAGGGCCACGTGCCAGGCCCGGGGCTGGCGGCTAC TCAGCAGCCCTCCTCACCCCGTCTGGGGTTCAGCCCCTCCTCTGCCACCTCCCCTATCCACCCAGCCCATTCTCTCTCC TGTCCAACCTAACCCCTT ApaI SNP

11 Results Ld N PCR product 695bp Ld Ld ApaI Digestion Possible Outcomes: T 695bp G 482bp 213bp

12 Results 100% 90% VDR ApaI genotype GG is linked to low fibrosis 80% 70% 60% 50% 40% 30% 20% high fibrosis (n=32) low fibrosis (n=35) 10% 0% TT GG TG P = 0.032

13 Results 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% F4 (n=24) F0-1 (n=25) VDR ApaI TT and TG genotypes that are linked to advanced fibrosis and cirrhosis 0% TT GG TG P=0.006 P=0.016 P=0.006

14 Conclusion VDR ApaI genotype GG is linked to low fibrosis progression, in contrast to the TT and TG genotypes that are linked to advanced fibrosis and cirrhosis.

15 Acknowledgements Biochemistry and Molecular Virology Molecular Biology and Genetics P. Mavromara K. Katsani M. Cheilas E. Filippopoulou Medical Biology Department of Medicine S. Veletza I. Karakasiliotis E. Gatzidou T. Georgoudis Internal Medicine General University Hospital K. Mimidis T. Mylopoulou

16 Thank you for your attention!!!

Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome

Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome ORIGINAL ARTICLE Annals of Gastroenterology (2018) 31, 1-5 Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome Theodora Mylopoulou a, Vasileios Papadopoulos b, Katerina

More information

Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection

Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi

More information

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and

More information

HEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014

HEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014 HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae

More information

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN

More information

Hepatitis C in Australia:

Hepatitis C in Australia: Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated

More information

Hepatitis C Management and Treatment

Hepatitis C Management and Treatment Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause

More information

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob: Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).

More information

Hepatitis C. Core slides

Hepatitis C. Core slides Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and

More information

Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir. Moreno 1

Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir. Moreno 1 Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir Jonas Schreiber 1, John McNally 2, Krishna Chodavarapu 2, Evguenia Svarovskaia 2, Christophe Moreno 1 Affiliations 1

More information

ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT

ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research

More information

Hepatitis C in Disclosures

Hepatitis C in Disclosures Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor

More information

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr

More information

ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?

ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL

More information

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

Clinical Immunology & Research

Clinical Immunology & Research Review Article Clinical Immunology & Research Gene Polymorphism of Responder, Relapser and Non-Responder of Chronic Hcv Infection among Ethnic Tribes of Punjab, Pakistan Ghazala Rubi * and Muhammad Aslamkhan

More information

Vicente Soriano Department of Infectious Diseases

Vicente Soriano Department of Infectious Diseases Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral

More information

RESEARCH ARTICLE. Rattanaporn Kiatbumrung 1, Natthaya Chuaypen 1, Sunchai Payungporn 1, Anchalee Avihingsanon 2, Pisit Tangkijvanich 1 * Abstract

RESEARCH ARTICLE. Rattanaporn Kiatbumrung 1, Natthaya Chuaypen 1, Sunchai Payungporn 1, Anchalee Avihingsanon 2, Pisit Tangkijvanich 1 * Abstract RESEARCH ARTICLE Editorial Process: Submission:01/19/2018 Acceptance:07/23/2018 The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection

More information

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology

More information

The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page

The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page 7842-7849 Comparison between clinical and biochemical versus interleukin 28B as a predictive factor of virological response to

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C

More information

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis

More information

The Changing World of Hepatitis C

The Changing World of Hepatitis C The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures

More information

Hepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...

Hepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re... Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional

More information

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious

More information

Hepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain

Hepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain Hepatitis Delta Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain Disclosures Member of speaker bureau and advisory board for: Roche, Boehringer, Gilead, Viiv,

More information

Treatment of chronic hepatitis B 2013 update

Treatment of chronic hepatitis B 2013 update 22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

Dr Kate Childs. King s College Hospital NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014

Dr Kate Childs. King s College Hospital NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Kate Childs King s College Hospital NHS Foundation Trust, London 1-4 April 2014, Arena and Convention Centre Liverpool Decrease in both IP-10 and 25(OH)D

More information

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at: ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis

More information

THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE

THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF

More information

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment

More information

Genotype 4. Sanaa Kamal, M.D., Ph.D. Professor. Ain Shams University, Cairo, Egypt Tufts School of Medicine

Genotype 4. Sanaa Kamal, M.D., Ph.D. Professor. Ain Shams University, Cairo, Egypt Tufts School of Medicine Optimal Therapy in Hepatitis C Genotype 4 Sanaa Kamal, M.D., Ph.D. Professor Ain Shams University, Cairo, Egypt Tufts School of Medicine Boston; USA HCV Genotype 4 True or False HCV-G4 is limited to Africa

More information

Clinical dilemmas in HBeAg-negative CHB

Clinical dilemmas in HBeAg-negative CHB Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department

More information

Persistent Infections

Persistent Infections Persistent Infections Lecture 17 Biology 3310/4310 Virology Spring 2017 Paralyze resistance with persistence WOODY HAYES Acute vs persistent infections Acute infection - rapid and self-limiting Persistent

More information

Genetic Determinants in HCV

Genetic Determinants in HCV Genetic Determinants in HCV Lynn E. Taylor, MD Assistant Professor of Medicine Warren Alpert Medical School of Brown University The Miriam Hospital Providence, RI April 27, 2011 Disclosure My presentation

More information

Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne

Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment

More information

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR 29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician

Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician Outline: Virology HBV + pregnancy HCV + new treatments Cases Hepatitis Foundation HBV: virus HBsAg far in excess of complete virions,

More information

Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC

Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT

More information

«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients

«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients «Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients Δημήτρησ Ν. αμωνάκησ Γαςτρεντερολογική κλινική Πανεπιςτημίου Κρήτησ Outline Epidemiology Risk factors

More information

Bioinformation by Biomedical Informatics Publishing Group

Bioinformation by Biomedical Informatics Publishing Group Predicted RNA secondary structures for the conserved regions in dengue virus Pallavi Somvanshi*, Prahlad Kishore Seth Bioinformatics Centre, Biotech Park, Sector G, Jankipuram, Lucknow 226021, Uttar Pradesh,

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

National Clinical Guidelines for the treatment of HCV in adults. Version 5

National Clinical Guidelines for the treatment of HCV in adults. Version 5 National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators

More information

Some HCV History 1970s: many cases reported called non-a, non-b hepatitis

Some HCV History 1970s: many cases reported called non-a, non-b hepatitis Hepatitis C virus 1 Some HCV History 1970s: many cases reported called non-a, non-b hepatitis 1988: hepatitis C virus identified 1990: antibody screening tests available 1992: better tests to insure safety

More information

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:

More information

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,

More information

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS The International Network on Hepatitis in Substance users (INHSU) Olav Dalgard Oslo Grebely J et al Int J

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),

More information

Should Elderly CHC Patients (>70 years old) be Treated?

Should Elderly CHC Patients (>70 years old) be Treated? Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,

More information

Epatite Cronica C Definizione dei Prototipi Clinici per la Personalizzazione Terapeutica Genotipo 4. Gloria Taliani Sapienza Università di Roma

Epatite Cronica C Definizione dei Prototipi Clinici per la Personalizzazione Terapeutica Genotipo 4. Gloria Taliani Sapienza Università di Roma Epatite Cronica C Definizione dei Prototipi Clinici per la Personalizzazione Terapeutica Genotipo 4 Gloria Taliani Sapienza Università di Roma Genotype 4 HCV Virus Predictors of SVR IL28B, Insulin Resistance,

More information

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design

More information

Update in hepatitis C virus infection

Update in hepatitis C virus infection Update in hepatitis C virus infection Eoin Feeney Consultant in Infectious Diseases St. Vincent s University Hospital Overview Natural history Diagnosis, screening, staging Management Barriers going forward

More information

Treatment of chronic hepatitis C in HIV co-infected patients

Treatment of chronic hepatitis C in HIV co-infected patients Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV

More information

Viral and Host Factors in Vulvar Disease DR MICHELLE ETHERSON 26 TH OF APRIL 2016

Viral and Host Factors in Vulvar Disease DR MICHELLE ETHERSON 26 TH OF APRIL 2016 Viral and Host Factors in Vulvar Disease DR MICHELLE ETHERSON 26 TH OF APRIL 2016 Human Papillomavirus (HPV) Small non-enveloped Double stranded DNA Virus Genome 8000 basepairs 8 coding genes, Early (E)

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Antiviral Therapy 2012; 17: (doi: /IMP2018)

Antiviral Therapy 2012; 17: (doi: /IMP2018) ntiviral Therapy 12; 17:541 547 (doi: 1.3851/IMP18) Short communication The vitamin D receptor gene bt (CC) haplotype impairs the response to pegylated-interferon/ ribavirin-based therapy in chronic hepatitis

More information

QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA

QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:

More information

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor

More information

Hepatitis C Virus SARS-Co Virus. Neerja Kaushik-Basu Biochemistry and Molecular Biology Oct

Hepatitis C Virus SARS-Co Virus. Neerja Kaushik-Basu Biochemistry and Molecular Biology Oct Hepatitis C Virus SARS-Co Virus Neerja Kaushik-Basu Biochemistry and Molecular Biology kaushik@umdnj.edu d Oct 30 2008 Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

Treatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience)

Treatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience) Korean Association of HBP Surgery President: Dong Wook Choi, MD, PhD, Samsung Medical Center Session : 09:50-10:50, 2 nd /3, Apr 27, 2013 Venue: Lotte Hotel, Jeju Island, Korea Session: Prevention of original

More information

HEPATITIS C TREATMENT GUIDANCE

HEPATITIS C TREATMENT GUIDANCE HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product

More information

Pre-Assessment Review: Microbiology, Part 2: Virology. Dr. David Hillyard

Pre-Assessment Review: Microbiology, Part 2: Virology. Dr. David Hillyard Pre-Assessment Review: Microbiology, Part 2: Virology Dr. David Hillyard 1. Mutations or deletions within which gene are associated with the hyper-toxin producing strain of Clostridium difficile? a. tcda

More information

New York State HCV Provider Webinar Series. Side Effects of Therapy

New York State HCV Provider Webinar Series. Side Effects of Therapy New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related

More information

CDC website:

CDC website: Hepatitis B virus CDC website: http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_b/slide_1.htm Relevance Key Features es of Hepatitis t B Virus 250 million people infected worldwide. In areas of

More information

ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV

ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:

More information

Section 3: Testing and Diagnosis of Hepatitis C

Section 3: Testing and Diagnosis of Hepatitis C Section 3: Testing and Diagnosis of Hepatitis C Dr. Jules Alla Kouadio (Médecins du Monde) Training Hepatitis C and HR for PWUD, 20 th -24 th Sept. 2016, Nairobi, Kenya Learning objective of the session

More information

Updates in the Treatment of Hepatitis C

Updates in the Treatment of Hepatitis C Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose

More information

Nucleic acid Strands Family Example Accession Base pairs

Nucleic acid Strands Family Example Accession Base pairs Table 16.1 Classification of viruses based on nucleic acid composition. Note that NCBI BioProject accessions begin PRJNA and typically encompass several segments. Adapted from Schaechter et al. (1999)

More information

National Clinical Guidelines for the treatment of HCV in adults. Version 4

National Clinical Guidelines for the treatment of HCV in adults. Version 4 National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN

More information

How to optimize treatment for HCV Genotype 4

How to optimize treatment for HCV Genotype 4 How to optimize treatment for HCV Genotype 4 Paris Hepatitis Conference Pr Tarik Asselah 14 janvier 2014 MD, PhD Service d Hépatologie & INSERM U773 University Paris Diderot Hôpital Beaujon, Clichy tarik.asselah@bjn.aphp.fr

More information

SYNOPSIS Final Clinical Study Report for Study AI444031

SYNOPSIS Final Clinical Study Report for Study AI444031 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study

More information

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis

More information

Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration

Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration Emi Tafoya, Yasong Lu, Melody Luo, Premkumar Narasimhan, Neelima

More information

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha

More information

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority

More information

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses

More information

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

Current Treatments for HCV

Current Treatments for HCV Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,

More information

EPIDEMIOLOGICAL HETEROGENEITY OF INFECTIONS WITH HEPATITIS B AND D VIRUSES IN BRAZIL

EPIDEMIOLOGICAL HETEROGENEITY OF INFECTIONS WITH HEPATITIS B AND D VIRUSES IN BRAZIL PREVENTION AND CONTROL OF VIRAL HEPATITIS IN BRASILAND OTHER LATIN AMERICAN COUNTRIES BRASÍLIA, BRAZIL 21 DE MARCH 2014 EPIDEMIOLOGICAL HETEROGENEITY OF INFECTIONS WITH HEPATITIS B AND D VIRUSES IN BRAZIL

More information

Hepatitis C SYMPTOMS COMPLICATIONS

Hepatitis C SYMPTOMS COMPLICATIONS Hepatitis C Hepatitis simply means "inflammation of the liver". Hepatitis C is a virus that was isolated in 1989. Since then, a tremendous amount has been learned about the virus. SYMPTOMS Hepatitis C

More information

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,

More information

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

2. Liver blood tests and what they mean p2 Acute and chronic liver screen Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised

More information

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients

More information

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

General Statement for Drugs for the Treatment of Hepatitis C

General Statement for Drugs for the Treatment of Hepatitis C General Statement for Drugs for the Treatment of Hepatitis C Use the following criteria to determine patient eligibility for subsidisation under the PBS for hepatitis C treating agents. By writing a PBS

More information

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370: Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV

More information

9/29/2014. Patterns of hepatitis C virus RNA levels during acute infection: the InC 3 study. Background. Background. Background

9/29/2014. Patterns of hepatitis C virus RNA levels during acute infection: the InC 3 study. Background. Background. Background atterns of hepatitis C virus RNA levels during acute infection: the InC 3 study Behzad Hajarizadeh 1, Bart Grady 2, Kimberly age 3, Arthur Y. Kim 4, Barbara H. McGovern 5,6, Andrea L. Cox 7, Thomas M.

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

VIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS?

VIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS? VIRAL AND AUTOIMMUNE HEPATITIS Arthur M. Magun, M.D. Clinical Professor of Medicine WHAT IS HEPATITIS? Inflammation of the liver Almost always, inflammation implies elevation in liver enzymes AST and ALT

More information

Analysis of Hepatitis C Virus using Data mining algorithm -Apriori, Decision tree

Analysis of Hepatitis C Virus using Data mining algorithm -Apriori, Decision tree Analysis of Hepatitis C Virus using Data mining algorithm -Apriori, Decision tree ABSTRACT Ha YeongJeong and Tae Seon Yoon Hankuk Academy of Foreign Studies, Yongin, Gyeonggi, Republic of Korea Hepatitis

More information

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D. Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,

More information

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago

More information

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL

More information